UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Qin, S; Finn, RS; Kudo, M; Meyer, T; Vogel, A; Ducreux, M; Macarulla, TM; ... Zhu, AX; + view all (2019) RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncology , 15 (16) pp. 1811-1822. 10.2217/fon-2019-0097. Green open access

[img]
Preview
Text
Meyer_RATIONALE 301 stud. Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma_VoR.pdf - Published version

Download (7MB) | Preview

Abstract

Advanced, unresectable hepatocellular carcinoma (HCC) has a poor prognosis with median life expectancy of approximately 1 year. Overexpression of PD-L1 in tumor cells and PD-1 on tumor-infiltrating T cells has been associated with poorer prognosis, more advanced disease and higher recurrence rates in HCC. Monoclonal antibodies against PD-1 have demonstrated antitumor activity in patients with solid tumors, including HCC. Tislelizumab, an investigational, humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1, has demonstrated preliminary antitumor activity in HCC. Here we describe a head-to-head Phase III study comparing the efficacy, safety and tolerability of tislelizumab with sorafenib as first-line treatment in unresectable HCC.

Type: Article
Title: RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.2217/fon-2019-0097
Publisher version: https://doi.org/10.2217/fon-2019-0097
Language: English
Additional information: © 2019 Future Science Group. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: HCC, PD-1, hepatocellular carcinoma, tislelizumab
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10077677
Downloads since deposit
17Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item